UNSPSC 51384507: Fluprofen

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P69N9N4Y9Y. European Medicines Agency schedules Fluprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07737MIG. Fluprofen generally arises in the molecular formula C15H13FO2.

UNSPSC 51384507 Fluprofen is a Commodity code that nominally identifies a single nonsteroidal anti-inflammatory drug product, but recent state and local procurement activity under this code does not align with fluprofen procurement. The three most recent solicitations tagged to this code actually seek naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription program capabilities (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products across a multistate cooperative (Minnesota Multistate Cooperative Purchasing Alliance). The mismatch between the code's nominal scope and the actual work being solicited suggests either data-tagging error in state procurement platforms or that the code has been repurposed in practice to capture broader pharmaceutical and drug-related services. State and local governments are using this code primarily to solicit community health supplies, pharmacy benefit program innovation, and cooperative pharmaceutical distribution arrangements rather than fluprofen specifically.

Activity is concentrated in Florida, Texas, and Minnesota, with the most recent opportunity being Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2026 at 2:00 pm) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) seeking vendor capability information for a direct-to-manufacturer prescription program, positioning that solicitation as exploratory market research ahead of a formal RFP. The Minnesota Multistate Cooperative Purchasing Alliance released an RFP (S1070000015802, posted January 20, 2026, due March 26, 2026) for generic pharmaceuticals and OTC products to be distributed through three authorized wholesalers, with contract effectiveness July 1, 2026. Issuing bodies span county health departments and state health commissions, suggesting activity concentrated in health and human services functions at the state and county level. Because the recent opportunities show minimal relevance to fluprofen itself, the code's current market signal is limited and may not support focused business development without clarification of how the code is being applied in practice.